Boston's drug-eluting stent gets priority status:
This article was originally published in Clinica
Boston Scientific's PMA application for its TAXUS paclitaxel-eluting coronary stent has been granted expedited review status by the US FDA. The agency's decision implies it views the technology as "breakthrough" potentially. Although the status does not guarantee a faster approval from the FDA, it ensures that the agency's resources are assigned to the review as a priority, says Boston.